Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Alnylam, Alcon, Kikkoman, and More

Premium

Title: Compositions and Methods for Inhibiting Expression of Factor VII Gene

Patent Number: 8,334,273

Filed: Dec. 19, 2010

Lead Inventor: Antonin de Fougerolles, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the factor VII gene,” the patent's abstract states.


Title: Lactic Acid Bacteria-Derived Double-Stranded RNA

Patent Number: 8,334,371

Filed: Jan. 26, 2010

Lead Inventor: Ikuko Masuda, Kikkoman

The invention, the patent's abstract states, comprises “an immunoregulator that is safe and efficiently incorporated into cells, along with a production process thereof. ... Double-stranded RNA derived from lactic acid bacteria, an immunoregulator having for an active ingredient thereof double-stranded RNA derived from lactic acid bacteria, and a process for producing double-stranded RNA derived from lactic acid bacteria are provided. Bacteria cells of a strains of lactic acid bacteria such as genus Tetragenococcus, genus Pediococcus, genus Lactobacillus, genus Streptococcus, or genus Leuconostoc are able to produce double-stranded RNA having immunoregulatory action therein.”


Title: Nuclease-Resistant Double-Stranded Ribonucleic Acid

Patent Number: 8,334,373

Filed: March 2, 2011

Lead Inventor: Hans-Peter Vornlocher, Alnylam Pharmaceuticals

“This invention relates to modified double-stranded oligoribonucleic acid having improved stability in cells and biological fluids, and methods of making and identifying dsRNA having improved stability, and of using the dsRNA to inhibit the expression or function of a target gene,” according to the patent's abstract.


Title: Low-Density Lipoprotein Receptor-Mediated siRNA Delivery

Application Number: 20120315288

Filed: Aug. 13, 2012

Inventor: Jon Chatterton, Alcon

“The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo,” the patent application's abstract states. “The conjugates comprise a ligand that can bind to a low-density lipoprotein receptor or LDLR family member. Therapeutic uses for the conjugates are also provided.”


Title: Methods and Compositions for Treating Insects

Application Number: 20120316220

Filed: Feb. 2, 2012

Lead Inventor: Donna Ward, Alnylam Pharmaceuticals

The invention, the patent application's abstract states, relates to “methods and compositions for modulating gene expression in insects by administering a composition comprising an RNA effector molecule and a delivery agent. Methods are provided for controlling pest populations by inhibiting insect growth, development, survival, reproduction, and/or viability. Also provided herein are methods for treating or preventing disease in an insect caused by a pathogen or by external factors.”


Title: Novel RNAi Therapeutic for Treatment of Hepatitis C Infection

Application Number: 20120316222

Filed: July 26, 2012

Inventor: Hengli Tang, Florida University

The invention comprises “small interfering RNAs or small hairpin RNA … that target human cyclophilin A to inhibit hepatitis C infection,” the patent application's abstract states. “Such siRNAs and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNAs and shRNAs may be formulated as naked compositions or pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing, inhibiting, [and] preventing ... HCV infection using such siRNAs and shRNAs and compositions comprising same are also provided.”

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.